A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms STRATOS2
- Sponsors AstraZeneca
- 10 Aug 2017 Planned End Date changed from 28 Sep 2017 to 21 Sep 2017.
- 23 Mar 2017 Planned primary completion date changed from 1 May 2017 to 30 Apr 2017.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.